Evidence mapPaperPMID 39683571Full record

ArticleNutrients2024

Impact of Dietary Niacin on Metabolic Dysfunction-Associated Steatotic Liver Disease in Mediterranean Subjects: A Population-Based Study.

Maria Antentas, Marina Idalia Rojo-López, Pau Vendrell, Minerva Granado-Casas, Idoia Genua, Berta Fernandez-Camins, Joana Rossell, Julia Niño-Narvión, Estefanía Moreira, Esmeralda Castelblanco and 5 more

Abstract read
In one paragraph

Article in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Maria AntentasInstitut de Recerca Sant Pau (IR SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain.
Marina Idalia Rojo-LópezInstitut de Recerca Sant Pau (IR SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain.
Pau VendrellGrup de Diabetis d'Atenció Primària (DAP-Cat), Unitat de Suport a la Recerca Barcelona, Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, 08007 Barcelona, Spain.
Minerva Granado-CasasGrup de Diabetis d'Atenció Primària (DAP-Cat), Unitat de Suport a la Recerca Barcelona, Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, 08007 Barcelona, Spain.ORCID 0000-0003-3447-5728
Idoia GenuaInstitut de Recerca Sant Pau (IR SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain.ORCID 0000-0001-6834-561X
Berta Fernandez-CaminsInstitut de Recerca Sant Pau (IR SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain.ORCID 0000-0001-7535-6181
Joana RossellInstitut de Recerca Sant Pau (IR SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain.ORCID 0000-0003-1500-6379
Julia Niño-NarviónInstitut de Recerca Sant Pau (IR SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain.ORCID 0000-0001-6514-0731
Estefanía MoreiraInstitut de Recerca Sant Pau (IR SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain.
Esmeralda CastelblancoDivision of Endocrinology, Metabolism and Lipid Research, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0002-2061-6270
Emilio OrtegaDepartment of Medicine, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.ORCID 0000-0002-2217-8905
Bogdan VlachoInstitut de Recerca Sant Pau (IR SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain.ORCID 0000-0003-3768-8112
Nuria AlonsoDepartment of Endocrinology and Nutrition, Hospital de la Germans Trias i Pujol, 08916 Barcelona, Spain.
Didac MauricioInstitut de Recerca Sant Pau (IR SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain.ORCID 0000-0002-2868-0250
Josep JulveInstitut de Recerca Sant Pau (IR SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain.ORCID 0000-0002-6531-2246

Funding

Agencia Estatal de Investigación, Consolidación Investigadora 2022 MCIN/AEI/10.13039/501100011033 - CNS2022-135559CIBER-Consorcio Centro de Investigación Biomédica en Red CB15/00071Instituto de Salud Carlos III PI15/0625Instituto de Salud Carlos III PI18/0328Instituto de Salud Carlos III PI21/00770Instituto de Salud Carlos III PI21/00817Instituto de Salud Carlos III PI24/00156Pla Estratègic de Recerca i Innovació en Salut (PERIS) 2021-2024 SLT017/20/000107
6 · The paper itself

Abstract

backgroundThe impact of dietary niacin on metabolic dysfunction-associated steatotic liver disease (MASLD) is elusive. This sub-study aimed to investigate the relationship between dietary niacin intake and the presence of MASLD in participants from two Catalonian cohorts.

methodsA total of 222 subjects with MASLD were age- and sex-matched to 222 non-MASLD subjects. Dietary nutrients were analyzed using a validated food frequency questionnaire (FFQ). Dietary niacin and other nutrients were adjusted for total energy intake. MASLD was defined by a Fatty Liver Index (FLI) of >60 and by having at least one component of metabolic syndrome. The association between niacin intake (distributed into tertiles) and the presence of MASLD was assessed using multivariate logistic regression. Potential non-linear relationships were also analyzed through restricted cubic spline regression (RCS).

resultsOur data revealed that subjects with MASLD had worse metabolic profiles. The dietary intake of niacin did not differ between subjects with and without MASLD. Even after adjusting for different confounding variables, i.e., sociodemographic variables, smoking status, physical activity, and cardiometabolic comorbidities, no significant associations were observed between higher intakes of niacin (tertiles 2 and 3) and the presence of MASLD: odds ratio (95% confidence) second tertile: 0.99 (0.89-1.09); third tertile: 0.98 (0.89-1.10). However, RCS analysis uncovered a significant non-linear dose-response association between dietary niacin intake and odds of MASLD. Specifically, such analysis revealed that MASLD risk was decreased in subjects with niacin intake values of <35 mg/day.

conclusionsOur data showed that dietary niacin intake was associated with lower odds of MASLD in a Mediterranean population; however, our logistic regression analysis failed to reveal significant associations between the intake of niacin and the risk of MASLD. Further research is warranted to establish a causal relationship between dietary niacin interventions and MASLD.

Indexed as

NiacinAdultAgedCross-Sectional StudiesDietDiet, MediterraneanFatty LiverFemaleHumansMaleMetabolic SyndromeMiddle AgedNon-alcoholic Fatty Liver DiseaseSpainNiacincase-control studyfatty liverhepatic steatosisniacintryptophanvitamin B3

Identifiers

PMID39683571
PMCPMC11644089

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.